HER-2 overexpression	Hormone Receptor Negative Breast Cancer	HER-2 overexpression	Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Negative Breast Cancer	HER-2 overexpression	Hormone Receptor Negative Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
HER-2 underexpression	Hormone Receptor Negative Breast Cancer	HER-2 underexpression	Hormone Receptor Negative Breast Cancer	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
HER-2 amplification + HER-2 R157W	Hormone Receptor Negative Breast Cancer	HER-2 amplification + HER-2 R157W	Hormone Receptor Negative Breast Cancer	pyrotinib Sensitive: C4 – Case Studies pyrotinib Sensitive : C4	pyrotinib Sensitive: C4 – Case Studies pyrotinib Sensitive : C4

Hormone Receptor Negative Breast Cancer

Associations(4)